Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04741074 · ClinicalTrials.gov registry record · Phase 3
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
A Phase 3 study, sponsored by Geisinger Clinic.
- Terminated
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
NCT04741074 is a Phase 3 study that was terminated before completion, run by Geisinger Clinic. The registered enrollment target is 15 participants.
The verdict
NCT04741074, a Phase 3 study, was terminated before completion, sponsored by Geisinger Clinic.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
Study Summary
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients' eligibility for kidney transplantation at the end of 9 months.
Interventions
- DRUG Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- DRUG Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-07-23 |
| Est. Completion | 2023-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04741074
The ClinicalTrials.gov registry entry for NCT04741074 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geisinger Clinic, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution is the first listed.
NCT04741074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04741074 about?
NCT04741074 is a clinical study titled "Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy". This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients' eligibi...
What is the current status of trial NCT04741074?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2021-07-23. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT04741074?
The interventions under investigation include: Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution (DRUG), Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution (DRUG).
Who is sponsoring clinical trial NCT04741074?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.